Remote & Decentralized Monitoring
Clinical nurses who follow your patients between every visit.
Study sites see a participant for an hour. The rest of the protocol happens somewhere else. Premier Bioservices staffs that gap with licensed clinical nurses conducting telehealth and in-home visits, reviewing remotely captured data, and escalating safety signals on a defined pathway — under investigator oversight, before approval and long after it.
- Regulatory basis
- FDA final guidance, September 2024
- Quality framework
- ICH E6(R3) risk-based oversight
- Records
- 21 CFR Part 11 and HIPAA aligned
- Follow-up windows
- 12 weeks to multi-year
Why this is standard practice now
Decentralized elements are no longer an exception request.
In September 2024 the FDA finalized Conducting Clinical Trials With Decentralized Elements, superseding the 2023 draft. The guidance is explicit: telehealth visits with trial personnel, in-home visits by remote trial personnel, visits with local healthcare providers, and remote data capture through digital health technologies are all legitimate ways to execute a protocol. Regulatory requirements do not change because activity moved off-site.
ICH E6(R3) pushes in the same direction from the quality side. Sponsors are expected to design quality in, identify critical-to-quality factors, set pre-specified tolerance limits, and apply oversight proportionate to risk rather than uniformly. Centralized and remote monitoring is the mechanism that makes that practical.
What both documents demand is infrastructure. FDA is clear that it is not enough to send a nurse to someone's home: delegation must be documented, staff must be trained and credentialed, escalation pathways must exist before they are needed, and records must be accessible for monitor review and inspection. That infrastructure is what we provide.
Scope of service
Everything a protocol needs between site visits.
Whatever the study requires, for however long it requires it — before approval and long after.
Pre-approval
Interventional studies, Phase II through IV
Enrollment gets a study started. Retention and clean data are what finish it. Our nurses own the space between site visits.
- Telehealth follow-up visits and protocol-driven symptom review
- In-home visits by remote trial personnel where the protocol allows
- ePRO and patient-reported outcome collection, with active chasing of missing entries
- Remote wound imaging review and digital health technology data triage
- Adherence, dosing reminder, and retention contact on a defined cadence
- Adverse event intake, safety follow-up, and escalation to the investigator
- Concomitant medication and protocol deviation capture at the point it happens
- Coordination with local healthcare providers performing delegated activities
Post-approval
Surveillance, registries, and long-term follow-up
Commitments that outlive the pivotal trial still need staffing. Multi-year follow-up is a nursing problem long before it is a data problem.
- Post-market surveillance programs and safety reporting support
- Post-market clinical follow-up for medical devices
- Patient registries with scheduled longitudinal nurse contact
- Long-term extension and safety follow-up cohorts
- Real-world evidence and outcomes data collection
- Label-expansion and Phase IV observational study support
- Participant re-contact and re-consent campaigns
- Retention programs designed for cohorts followed across years
Centralized monitoring
Oversight you can show an inspector.
Under E6(R3) an oversight plan that is not visible in an action log does not exist. We build the log as we work.
Remote source data verification
Review against source through validated eSource and eISF systems, prioritized by criticality rather than applied uniformly to every field.
Quality tolerance limits
Pre-specified acceptable ranges at the trial level. When a metric drifts outside its range we evaluate whether the cause is systemic and document the determination.
Escalation pathways
Defined routes and timelines for adverse events, safety signals, and protocol deviations, with the investigator retaining responsibility and visibility throughout.
Delegation and training records
Current delegation logs, credential verification, and protocol-specific training documentation for every person performing a trial-related activity.
Performance signal review
Enrollment velocity, screen-failure patterns, query rates, and visit-window compliance reviewed on a set cadence, with outcomes recorded.
Telehealth licensure compliance
Remote visits conducted in accordance with the telehealth practice laws of the state in which the participant is located, including consent and identification requirements.
Where it matters most
Wound care is the clearest case for remote monitoring.
Chronic wound trials are slow, and the reasons are structural. Inclusion criteria are narrow. Participants carry heavy comorbidity burdens. Care is often urgent enough that a patient needs treatment before they can be screened. And the primary endpoint — complete closure, usually at twelve weeks — depends on assessments happening on schedule, week after week, for patients who frequently cannot travel easily.
US diabetic foot ulcer trials enroll a mean of 1.51 patients per site per month, with a median of 0.58. The published determinants of a faster enrolling wound study are consistent: more sites, and reduced participant travel burden. That is precisely the combination an SMO with a remote nursing team delivers.
Between-visit wound assessment is also now a solved technical problem. AI-assisted smartphone wound imaging can be captured by the patient or a visiting nurse and reviewed remotely, which means a stalling or deteriorating wound triggers intervention in days rather than at the next scheduled visit. Home health is the fastest-growing segment of chronic wound care for the same reason.
Patients enrolled per site per month in US diabetic foot ulcer trials. The median is 0.58. Trials using more sites and reducing participant travel burden enroll materially faster.
Systematic review of 397 DFU trials
Share of total clinical trial cost attributable to on-site monitoring alone — the reason remote source data review is a primary cost lever.
Compliance
The frameworks we operate inside.
Decentralized does not mean informal. Every element below is designed in before the first participant is consented.
FDA decentralized elements
Conducting Clinical Trials With Decentralized Elements, final guidance, September 2024.
ICH E6(R3) Good Clinical Practice
Quality by design, critical-to-quality factors, and risk-proportionate oversight.
21 CFR Part 11
Electronic records and electronic signatures, with validated systems and audit trails.
HIPAA
Protected health information handled under executed business associate agreements.
State telehealth practice law
Remote visits conducted under the licensure and consent rules of the participant's state.
Form FDA 1572 discipline
Clear separation between delegated local HCP activity and work requiring listed trial personnel.
Scope a program
Send us the follow-up schedule. We will staff it.
Whether it is a twelve-week healing endpoint or a five-year post-market registry, tell us what the protocol requires between visits and we will come back with a staffing and oversight plan.